IndieBio

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

MAA'VA is focused on creating innovative green building materials designed to serve as sustainable alternatives to concrete. The company incorporates recycled plastics, utilizes carbon sequestration techniques, and promotes the upcycling of manufacturing waste. By addressing pressing issues such as the river sand shortage, water scarcity, climate change, and rapid urbanization, MAA'VA aims to provide eco-friendly solutions for construction. Its materials are suitable for both traditional and three-dimensional printing methods, enabling clients to adopt more sustainable practices in their building projects.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

MAA'VA is focused on creating innovative green building materials designed to serve as sustainable alternatives to concrete. The company incorporates recycled plastics, utilizes carbon sequestration techniques, and promotes the upcycling of manufacturing waste. By addressing pressing issues such as the river sand shortage, water scarcity, climate change, and rapid urbanization, MAA'VA aims to provide eco-friendly solutions for construction. Its materials are suitable for both traditional and three-dimensional printing methods, enabling clients to adopt more sustainable practices in their building projects.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

JointechLabs, Inc. is a company that specializes in point-of-care regenerative medicine therapies, headquartered in Brandon, Florida. The organization develops innovative medical devices, including the MiniTC® for the United States and the Mini-Stem System® for international markets. These devices facilitate the processing of autologous body fat, enabling safe and efficient use in non-surgical orthopedic and aesthetic procedures within medical offices. By providing a closed-loop disposable system for human tissue processing, JointechLabs simplifies the creation of high-quality injectable fat grafts and fat-derived stem cells, making individualized cell and tissue-based therapies more accessible and cost-effective for hospitals and clinics. Additionally, the company is expanding its product pipeline to include biologic drugs and 3D bioprinted products aimed at orthopedic, wound healing, and plastic and reconstructive surgery applications.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

JointechLabs, Inc. is a company that specializes in point-of-care regenerative medicine therapies, headquartered in Brandon, Florida. The organization develops innovative medical devices, including the MiniTC® for the United States and the Mini-Stem System® for international markets. These devices facilitate the processing of autologous body fat, enabling safe and efficient use in non-surgical orthopedic and aesthetic procedures within medical offices. By providing a closed-loop disposable system for human tissue processing, JointechLabs simplifies the creation of high-quality injectable fat grafts and fat-derived stem cells, making individualized cell and tissue-based therapies more accessible and cost-effective for hospitals and clinics. Additionally, the company is expanding its product pipeline to include biologic drugs and 3D bioprinted products aimed at orthopedic, wound healing, and plastic and reconstructive surgery applications.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Amino Labs Inc. is a biotechnology company founded in 2015 and based in Canada that focuses on making genetic engineering accessible to a wider audience. The company has developed an intuitive bioengineering mini-lab, a compact continuous bioreactor designed to facilitate bacterial transformations and the continuous growth of various cultures. This user-friendly equipment allows individuals, including those as young as eight, to experiment with genetic engineering, fostering a new generation of bioengineers. The bioreactor serves as a countertop-sized laboratory, providing educational opportunities to learn about DNA, genes, and cell theory, while enabling users to create a diverse range of products, including fragrances, flavors, materials, and medicines. By democratizing access to biotechnology, Amino Labs aims to contribute to personalized manufacturing and address significant global challenges related to food, fuel, and medicine.

Pembient, Inc. is a biotechnology company founded in 2015 and based in Seattle, Washington, that specializes in producing synthetic wildlife products, including rhino horn and elephant ivory. Utilizing advances in biotechnology, Pembient fabricates these materials through DNA and 3D-printing techniques, creating carvable horns suitable for durable goods such as jewelry and libation cups. The company's mission is to combat the illegal wildlife trade, a significant black market valued at $20 billion, by offering affordable alternatives that can deter poaching. By replacing traditional wildlife products with bio-fabricated options, Pembient aims to promote sustainable commerce and support wildlife conservation efforts.